1-13 of 13
John Francis Seymour, MBBS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Years

Gilles Andre Salles, MD PhD, John Francis Seymour, MBBS, Pierre Feugier, MD, Fritz Offner, MDhD, Armando Lopez-Guillermo, David Belada, MD PhD, Luc Xerri, MD PhD, Reda Bouabdallah, MD, John Catalano, Pauline Brice, MD, Corinne Haioun, Alejandro Martín, MD PhD, Lars Moller Pedersen, Alain Jacques Delmer, MD, David Simpson, MBChB, Sirpa Leppa, MD, Pierre Soubeyran, MD PhD, Rene-Olivier Casasnovas, MD, Tanin Intragumtornchai, MD, Vincent Ribrag, Maria Gomes Silva, Emmanuelle Nicolas-Virelizier, MD, Thomas Lister, MD, Jane Estell, Gustavo Milone, MD, Anne Sonet, MD, Julie Assemat, Harald Zeuner, Bertrand Coiffier, MD PhD, Herve Tilly
Journal: Blood
Blood (2017) 130 (Supplement 1): 486.
https://doi.org/10.1182/blood.V130.Suppl_1.486.486
Published: 2017
Journal Articles

Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy

Gilles Andre Salles, MD, PhD, John Francis Seymour, MBBS, FRACP, PhD, Pierre Feugier, MD, PhD, Fritz Offner, MD, Armando Lopez-Guillermo, MD, PhD, David Belada, M.D., Ph.D., Luc Xerri, MD, PhD, Reda Bouabdallah, MD, John Catalano, MBBS FRACP FRCPA, Brice Pauline, MD, Dolores Caballero, MD, PhD, Corinne Haioun, MD, PhD, Lars Moller Pedersen, Alain Delmer, MD, David Simpson, Sirpa Leppa, Pierre Soubeyran, Anton Hagenbeek, MD, PhD, Olivier Casasnovas, MD, Tanin Intragumtornchai, MD, Christophe Ferme, MD, Maria Gomes da Silva, Catherine Sebban, MD, Andrew Lister, Jane A Estell, MBBS, FRCPA, FRACP, Gustavo Milone, Anne Sonet, MD, Bertrand Coiffier, MD, PhD, Herve Tilly, MD
Journal: Blood
Blood (2013) 122 (21): 509.
https://doi.org/10.1182/blood.V122.21.509.509
Published: 2013
Journal Articles

Updated Results of the PRIMA Study Confirms the Benefit of 2-Years Rituximab Maintenance In Follicular Lymphoma Patients Responding to Immunochemotherapy.

Gilles Andre Salles, MD, PhD, John Catalano, MBBS, FRACP, FRCPA, Pierre Feugier, MD, PhD, Fritz C Offner, MD, PhD, Reda Bouabdallah, MD, Dolores Caballero, MD, Pauline Brice, MD, Lars Moller Pedersen, MD, Corinne Haioun, MD, David Belada, MD, Alain Delmer, MD, David Simpson, FRACP, FRCPA, MB, CHB, Herve Tilly, MD, Sirpa Leppa, MD, Pierre Soubeyran, MD, Anton Hagenbeek, MD, PhD, Olivier Casasnovas, MD, Tanin Intragumtornchai, MD, MSc, Christophe Fermé, MD, Maria Gomes da Silva, MD, Catherine Sebban, MD, Andrew Lister, MD, Jane A Estell, MBBS, FRCPA, FRACP, Gustavo Milone, MD, Anne Sonet, MD, Armando Lopez-Guillermo, MD, John Francis Seymour, MBBS, FRACP, Ph, D, Luc Xerri, MD
Journal: Blood
Blood (2010) 116 (21): 1788.
https://doi.org/10.1182/blood.V116.21.1788.1788
Published: 2010
Journal Articles

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

Michael Hallek, MD, Guenter Fingerle-Rowson, MD, PhD, Anna- Maria Fink, MD, Raymonde Busch, Jiri Mayer, MD, Manfred Hensel, MD, Georg Hopfinger, MD, Georg Hess, MD, Ulrich von Gruenhagen, MD, Manuela A. Bergmann, MD, John Catalano, MD, Pier Luigi Zinzani, MD, Federico Caligaris Cappio, MD, John Francis Seymour, MBBS, Alain Berrebi, MD, Ulrich Jaeger, MD, Bruno Cazin, MD, Marek Trneny, MD, PhD, Anne Westermann, Clemens-Martin Wendtner, MD, Barbara F. Eichhorst, MD, Peter Staib, MD, Sebastian Boettcher, MD, Matthias Ritgen, MD, Stephan Stilgenbauer, MD, Myriam Mendila, MD, Michael Kneba, MD, PhD, Hartmut Döhner, MD, Kirsten Fischer, MD
Journal: Blood
Blood (2008) 112 (11): 325.
https://doi.org/10.1182/blood.V112.11.325.325
Published: 2008
Journal Articles

The Addition of Systemic High-Dose Methotrexate (HD-MTX) to Intrathecal Chemotherapy (IT) for Central Nervous System (CNS) Prophylaxis Substantilly Reduces CNS Recurrence Rates in Patients with at-Risk Aggressive Lymphoma: A Historically Controlled Prospective Study

Kirsten Herbert, MBBS, FRACP, PhD, Max Wolf, MBBS, FRACP, FRCPA, Dennis Carney, MBBS, FRACP, FRCPA, David Alan Westerman, MBBS, FRACP, FRCPA, Henry Januszewicz, MBBS, FRACP, FRCPA, Simon Harrison, MBBS, PhD, David Ritchie, MBChB, FRACP, FRCPA, PhD, H. Miles Prince, John Francis Seymour, MBBS, FRACP, PhD
Journal: Blood
Blood (2008) 112 (11): 3596.
https://doi.org/10.1182/blood.V112.11.3596.3596
Published: 2008
Journal Articles

Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response.

Susan Branford, Rebecca Lawrence, Andrew Grigg, John Francis Seymour, MBBS, Anthony Schwarer, Christopher Arthur, Zbigniew Rudzki, Timothy Hughes
Journal: Blood
Blood (2008) 112 (11): 2113.
https://doi.org/10.1182/blood.V112.11.2113.2113
Published: 2008
Journal Articles

Improved Relapse Free Survival Is Predicted by a Negative Pre-Transplant FDG-PET Scan Following Salvage Chemotherapy for Relapsed Diffuse Large B Cell Lymphoma (DLBCL) Treated with Autologous Stem Cell Transplantation.

Michael J. Dickinson, MBBS, Rosemary Hoyt, BN, Andrew Roberts, MBBS PhD, Andrew Grigg, MBBS, John Francis Seymour, MBBS PhD, Jeff Szer, MBBS BSc BMedSci, H. Miles Prince, MBBS(Hons)MD, David Ritchie, MBChB PhD
Journal: Blood
Blood (2007) 110 (11): 5115.
https://doi.org/10.1182/blood.V110.11.5115.5115
Published: 2007
Journal Articles

Prolonged Hematologic Toxicity from the Hyper-CVAD Regimen; Manifestations, Frequency, and Natural History in a Cohort of 125 Consecutive Patients.

Saar Gill, MBBS, Steven Lane, MBBS, Julie Crawford, MBBS, Peter Mollee, MBBS, Paula Marlton, MBBS, Gavin Cull, MBBS, Miles Prince, MBBS, MD, John Francis Seymour, MBBS, PhD
Journal: Blood
Blood (2006) 108 (11): 2441.
https://doi.org/10.1182/blood.V108.11.2441.2441
Published: 2006
Journal Articles

Two Year Data from a Prospective Safety Study Analyzing the Consequences of Imatinib Mesylate Inhibition of Sensitive Kinases Other Than bcr-abl in Patients with Previously Untreated Chronic Phase CML.

John Francis Seymour, MBBS, PhD, Andrew Grigg, MB BS, John Reynolds, Ph D, Anthony P. Schwarer, MB BS PhD, Richard Hermann, MB BS, Kerry McDonald Taylor, MB BS, Kenneth Francis Bradstock, MB BS PhD, Anthony K. Mills, MB BS, Rachel Koelmeyer, BSc, Kevin Lynch, Timothy Hughes, MBBS MD
Journal: Blood
Blood (2006) 108 (11): 2147.
https://doi.org/10.1182/blood.V108.11.2147.2147
Published: 2006
Journal Articles

A Comparison of Acute and Delayed Infection Rates among Patients with Indolent Lymphoid Malignancies Receiving Fludarabine(F) and Cyclophosphamide(C) with or without Rituximab(R).

Constantine S. Tam, MBBS, John Francis Seymour, MBBS, Michael Brown, RN, Philip Campbell, MBBS, John D. Scarlett, MBBS, Craig Underhill, MBBS, David Ritchie, MBBS, Rodney Bond, MBBS, Andrew Grigg, MBBS
Journal: Blood
Blood (2004) 104 (11): 3313.
https://doi.org/10.1182/blood.V104.11.3313.3313
Published: 2004
Journal Articles

Incidence, Natural History and Management of Cytomegalovirus (CMV) Dnaemia and Disease in Patients with Haematological Malignancies in the Non-Allogeneic Transplantation Setting.

John Francis Seymour, MBBS, FRACP, Ashley Ng, MBBS, BMedSci, Leon Worth, MBBS, Monica Slavin, MBBS, FRACP, H. Miles Prince, MBBS, FRACP, Karin Thursky, MBBS, FRACP
Journal: Blood
Blood (2004) 104 (11): 3837.
https://doi.org/10.1182/blood.V104.11.3837.3837
Published: 2004
Journal Articles

Prolonged Severe Pancytopenia and Myelodysplastic Features Following Alemtuzumab Therapy in Patients with Cutaneous T-Cell Lymphomas.

Simon D. Gibbs, MBBS, David Alan Westerman, MBBS, John Francis Seymour, MBBS, Miles Prince, MBBS, MD
Journal: Blood
Blood (2004) 104 (11): 2645.
https://doi.org/10.1182/blood.V104.11.2645.2645
Published: 2004
Journal Articles

Imatinib’s Potential Effects on Fertility, Immunity and Pulmonary Function: A Prospective Study in Patients with Previously Untreated CML.

John Francis Seymour, MBBS FRACP, Andrew Grigg, MBBS FRACP, John Reynolds, Jane Matthews, Anthony P. Schwarer, MBBS FRACP, Richard Herrmann, MBBS FRACP, Kerry McDonald Taylor, MBBS FRACP, Mark S. Hertzberg, MBBS FRACP, Anthony Mills, MBBS FRACP, Nancy Guzzo-Pernell, Michael Copeman, MBBS FRACP, Kevin Lynch, MBBS, Timothy Hughes, MBBS FRACP
Journal: Blood
Blood (2004) 104 (11): 1020.
https://doi.org/10.1182/blood.V104.11.1020.1020
Published: 2004